Purple Biotech Cash Flow-to-Debt Ratio
Purple Biotech cash flow-to-debt ratio. Purple Biotech (PPBT) has a Cash Flow-to-Debt Ratio of -1.28x as of June 2026, meaning its operating cash flow of $-2.50 Million could theoretically repay -1% of its total liabilities ($1.95 Million) in one year. Check Purple Biotech cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Purple Biotech (2013–2025)
Cash flow-to-debt ratio of Purple Biotech from 2013 to 2025. Historical debt coverage capacity for Purple Biotech across 13 annual periods. Also explore Purple Biotech (PPBT) equity growth momentum to track the company's year-over-year net asset growth rate.
Purple Biotech Cash Flow-to-Debt Ratio by Year (2013–2025)
Purple Biotech cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Purple Biotech. For the full cash flow conversion analysis, see cash efficiency ratio of Purple Biotech.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-5.54 Million | $7.91 Million | ▲ +79.9% |
| 2024 | -3.48x | $-14.37 Million | $4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | $-19.93 Million | $10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | $-16.73 Million | $7.52 Million | ▲ +25.7% |
| 2021 | -3.00x | $-15.25 Million | $5.09 Million | ▼ -0.3% |
| 2020 | -2.98x | $-12.09 Million | $4.05 Million | ▼ -106.3% |
| 2019 | -1.45x | $-5.58 Million | $3.86 Million | ▲ +36.5% |
| 2018 | -2.28x | $-8.48 Million | $3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | $-8.63 Million | $5.59 Million | ▲ +62.3% |
| 2016 | -4.10x | $-6.26 Million | $1.53 Million | ▼ -71.2% |
| 2015 | -2.39x | $-3.31 Million | $1.38 Million | ▲ +47.9% |
| 2014 | -4.59x | $-4.53 Million | $986.00K | ▼ -1026.9% |
| 2013 | -0.41x | $-512.00K | $1.26 Million | — |